Rahul Aggarwal MD
Assistant Professor of Hematology/Oncology, Director of STAND Clinic, UCSF
Join to View Full Profile
505 Parnassus AveRoom M987San Francisco, CA 94143
Phone+1 415-476-1000
Dr. Aggarwal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2010 - 2013- University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009
Northwestern University The Feinberg School of MedicineClass of 2006
Certifications & Licensure
CA State Medical License 2008 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jun 01
- Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer Start of enrollment: 2013 Oct 29
- Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
- Join now to see all
Publications & Presentations
PubMed
- Racial variation in the advanced prostate cancer genome.Emily M Feng, Jenny Vo-Phamhi, Aishwarya N Subramanian, Mikhail Dias, Adam Foye
Prostate Cancer and Prostatic Diseases. 2025-03-31 - Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study.Lena M Unterrainer, Andrea Farolfi, Tristan Grogan, Masatoshi Hotta, Loïc Djaileb
European Journal of Nuclear Medicine and Molecular Imaging. 2025-03-26 - Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostat...Rahul R Aggarwal, Jacqueline Vuky, David VanderWeele, Matthew Rettig, Elisabeth I Heath
Journal of Clinical Oncology. 2025-03-26
Lectures
- Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.2019 ASCO Annual Meeting - 6/1/2019
- DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant pr...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Radiation’s New Era in OncologyMarch 26th, 2025- Breaking the Boundaries Between Radiology and Oncology: GU Oncology Profiles Thomas a. Hope, MDApril 28th, 2022
- Androgen Deprivation Therapy and SARS-CoV-2 in Men with Prostate Cancer: Findings from the University of California Health System RegistryFebruary 8th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
